StockData

Inhibrx Biosciences vs Scholar Rock

INBX and SRRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INBX and SRRK compare

Scholar Rock is the larger company, worth 5.0 times as much as Inhibrx Biosciences ($5.5B against $1.1B).

Scholar Rock scores higher on the StockData Score (2 against 1 for Inhibrx Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINBXSRRK
Size and price
Market cap$1.1B$5.5B
Share price$74.18$45.08
Change, 1 year−6.3%20.5%
Change, 5 years93.5%67.1%
Beta (5Y)2.160.83
Employees110289
StockData Score
Total score12 (better)
Valuation score00
Growth score00
Performance score00
Health score12 (better)
Dividend score00
Valuation
P/B–21.6×
FCF yield−12.2%−5.4% (better)
Growth
Revenue growth, 5Y average−36.8%–
Profitability
Return on equity–−168%
Financial health
Debt / equity–0.77
Interest coverage−5.9× (better)−38.0×
Current ratio7.58 (better)7.02
Altman Z-score−1.026.59 (better)
Piotroski F-score11
Dividends and buybacks
Buyback yield–−4.6%
Shareholder yield0.00% (better)−4.6%
Ownership
Held by institutions97.4%114%
Held by insiders35.4%28.9%
Insider net buying, 12 months$6.1M (better)−$7.4M
Superinvestors holding1–
Short interest, % of float35.7%27.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.